SHUTING GU^1,2,#, JINGYI QIN^3,#, SAINAN GAO¹, ZHEN WANG^1,4, QI MENG^1,4, YAN LI^1,4, BING LU⁵, SONGLIN ZHOU^1,2,*, YUNZHAO XU^1,6,*

BIOCELL, Vol.46, No.3, pp. 689-697, 2022, DOI:10.32604/biocell.2022.016225 - 18 November 2021

Abstract Recently, abnormal expression of KIAA1199 has been detected in Epithelial Ovarian Cancer (EOC). However, the underlined anti-ovarian cancer mechanism of KIAA1199 remains to be enlightened. In our study, we performed to elucidate the effects of KIAA1199 on the advanced biological behavior of EOC cells through activation of the IL-6/STAT3 pathway. Confirmed by immunohistochemistry, KIAA1199 was highly expressed in ovarian borderline and malignant epithelial tumors. A retrospective analysis found that EOC patients with low expression of KIAA1199 had a significantly higher 5-year survival rate than those with high expression. Mechanistically, IL-6 was used to stimulate EOC More >

AJIT C. DHADVE^1,2, PRITHA RAY^1,2

BIOCELL, Vol.46, No.1, pp. 75-86, 2022, DOI:10.32604/biocell.2022.016346 - 28 September 2021

Abstract Progression, relapse, and therapy resistance are the most challenging features of cancer therapy that have been postulated to be driven by Cancer Stem Cell (CSC) population. This enigmatic subpopulation of cancer cells has therefore emerged as promising therapeutic candidate. We earlier reported enrichment of CSC-like side population (SP) with increasing resistance towards Cisplatin and Paclitaxel either alone or in combination in epithelial ovarian cancer (EOC) cells. This SP population is a small proportion of the total population of cancer cells characterised with high expression of drug transporters, a unique feature of stem cells and thereby… More >

HAN WANG, YINGYING ZHOU, SIYANG ZHANG, YA QI, MIN WANG^*

Oncology Research, Vol.29, No.4, pp. 275-289, 2021, DOI:10.32604/or.2022.03561 - 31 August 2022

Abstract Metastasis and paclitaxel (PTX) resistance are the main reason for the poor prognosis of ovarian cancer (OC). Evidence showed that RNA-binding proteins (RBPs) and long noncoding RNAs (lncRNAs) can modulate post-transcriptional regulation. The aim of this study was to determine the relationship among RBP, lncRNA and OC and to further guide clinical therapy. Immunohistochemistry revealed that pre-mRNA processing factor 6 (PRPF6) was upregulated in OC chemoresistant tissues and was closely related to advanced (Federation of International of Gynecologists and Obstetricians) FIGO stages and chemo-resistance. PRPF6 promoted progression, and PTX resistance in vitro and in vivo. And the… More >

XIAOPANG REN^#, WANJIAO HAO^#, JIN LIU, YE LI, BING WANG, XINHUI ZU, HUILING XUE^*

BIOCELL, Vol.45, No.3, pp. 521-526, 2021, DOI:10.32604/biocell.2021.012137 - 03 March 2021

Abstract Ovarian cancer was one of the most common malignant tumors in female reproductive organs. Moreover, epithelial ovarian cancer showed the highest mortality rate in gynecological tumors, posing serious threats to women’s life and health. Transient Receptor Potential Cation Channel Subfamily V Member 2 (TRPV2) and matrix metalloproteinase-2 MMP-2 have been found to play important roles in regulating the pathogenesis of most tumors, but there were few studies exploring the relationships of TRPV2 and MMP-2 in OC. Therefore, we evaluated the expression of TRPV2 and MMP-2 proteins in cancer tissues and adjacent normal tissues of OC… More >

MAYSON H. ALKHATIB^1,2,*, SALWA M. AL-HASHEMI¹, HANA M. GASHLAN¹

BIOCELL, Vol.45, No.3, pp. 695-703, 2021, DOI:10.32604/biocell.2021.014349 - 03 March 2021

Abstract Incorporation of etoposide (ETP) into nanoemulsion (NE) containing polyunsaturated fatty acids (PUFAs) may potentially augment its antiproliferation effect on the cancer cells. The current study aimed to examine the in vitro antitumor activity of a novel formulation (ETP-BC/EP-NE) produced by combining the anticancer drug (ETP) with NE (BC/EP-NE) consisting of the black currant seed and organic evening primrose oils. The produced formulas were physically characterized using zetasizer measurements. Their cytotoxic effect was testified at concentrations ranges from 0.0001 to 5 μM using CCK-8. Apoptotic and anti-invasion effects were evaluated using the assays of mitochondrial membrane potential,… More >

LIETING MA¹, MIAOLING LI^2,*, XINGLONG ZHENG³

BIOCELL, Vol.45, No.2, pp. 317-321, 2021, DOI:10.32604/biocell.2020.09313 - 19 February 2021

Abstract Ovarian cancer is a malignant cancer type and affects women’s lives in the world. Circular RNAs (circRNAs) have been involved with the progression of cancers. In our study, we are going to explore the functions of circATF6 in ovarian cancer. The qRT-PCR assay was used to detect expressions of genes. Actinomycin D and RNase R treatment were implemented to verify the circular RNA character of circATF6. Besides, Cell proliferation was assessed by colony formation assay and EdU assay. Silenced circATF6 could reduce the proliferation of ovarian cancer cells. In addition, inhibited circATF6 could promote the More >

ATTALLA EL-KOTT^1,2, EMAN ELBEALY³, FAHMY ELSAID^1,4, HAITHAM EL-MEKKAWY¹, ABD-EL-KARIM ABD-LATEIF⁵, ABDULALI TAWEEL⁶, HEBA KHALIFA², AHMAD KANDEEL⁵, KAREEM MORSY^1,7, ESSAM IBRAHIM^1,8,9, MASHAEL MOHAMMED BIN-MEFERIJ^10,*

BIOCELL, Vol.45, No.1, pp. 89-101, 2021, DOI:10.32604/biocell.2021.012516 - 26 January 2021

Abstract This study investigates if the anti-tumor effect of Pterostilbene in the SKOV3 ovarian cancer (OC) cell line involves inhibition of cell metabolism and tested in this effect involves modulating AMPK and Akt-induced regulation of mTORC1. Initially, SKOV3 cells were cultured in the humidified conditions in DMEM media for 24 h with or without increasing concentration of Pterostilbene. Then, the cells were incubated with Pterostilbene (IC₅₀ = 50 µM) under similar conditions with or without pre-incubation with Dorsomorphin, an AMPK inhibitor. In a dose-dependent manner, Pterostilbene inhibited SKOV3 cell survival and increased their lysate levels of lactate… More >

Lu, Xiaoqin¹, Wang, Fuying¹, Fu, Meizhou², Li, Yuankun¹, Wang, Lijun¹

Oncology Research, Vol.28, No.2, pp. 135-146, 2020, DOI:10.3727/096504019X15719983040135

Abstract This article was wihdrawn by the authors with the following Withdrawal Statement - The integrity of the current study is not acceptable. The authors intend to enrich the study to make it more valuable. Thus, the authors want to withdraw the current study. Please accept our apologies for this inconvenience and we hope for your understanding. Yours sincerely (on behalf of the authors), Xiaoqin Lu. More >

Yanli Wang^*, Jia Li^†, Chunling Xu^†, Xiaomeng Zhang^†

Oncology Research, Vol.28, No.7-8, pp. 823-825, 2020, DOI:10.3727/096504021X16240202940021

Abstract Increasing evidence indicates that the dysregulation of microRNAs is associated with the development and progression of various cancers. MicroRNA-139-5p (miR-139-5p) has been reported to have a tumor suppressive role in many types of cancers. The role of miR-139-5p in ovarian cancer (OC) is poorly understood. The purpose of the present study was to explore the expression of miR-139-5p and its function in OC. The results showed that miR-139-5p expression was markedly downregulated in OC tissues and cell lines. In addition, underexpression of miR-139-5p was significantly associated with FIGO stage, lymph mode metastasis, and poor overall… More >

Neslihan Duzkale^1,*, Nilnur Eyerci²

Oncologie, Vol.22, No.3, pp. 161-166, 2020, DOI:10.32604/oncologie.2020.014116

Abstract BRCA1 and BRCA2 tumor suppressor genes are responsible for a quarter of hereditary breast cancers. Double heterozygous (DH) pathogenic variant carrier status in these genes is an extremely rare condition, especially in non-Askenazi individuals. We report a woman patient with bilateral breast cancer that carries DH disease-causing variants in BRCA1/2 genes. The 45-year-old patient who was followed up with the diagnosis of metachronous bilateral breast cancer was diagnosed with cancer at the age of 39 and 43, respectively. BRCA1/2 genes of the patient were evaluated using Next-Generation Sequencing. In the patient, the c.2800C>T (p.Gln934Ter) pathogenic variant in BRCA1… More >